Farnworth Paul G, Wang Yao, Escalona Ruth, Leembruggen Pauline, Ooi Guck T, Findlay Jock K
Prince Henry's Institute of Medical Research, Clayton, Victoria, Australia.
Endocrinology. 2007 Nov;148(11):5355-68. doi: 10.1210/en.2007-0155. Epub 2007 Jul 26.
Inhibin antagonizes activin and bone morphogenetic protein actions by sequestering their type II receptors in high-affinity complexes with betaglycan, a coreceptor that inhibin shares with TGF-beta. To clarify the nature and extent of interactions between inhibin and TGF-beta, we therefore examined 1) the mutual competition between these ligands for binding, 2) the regulation of endogenous betaglycan expression by inhibin and TGF-beta isoforms, and 3) the consequences of such betaglycan regulation for subsequent inhibin binding in mouse Leydig (TM3), Sertoli (TM4), adrenocortical cancer (AC), and gonadotroph (LbetaT2) cell lines, chosen to model cellular targets for local and endocrine actions of inhibin. Recognized inhibin, activin, and TGF-beta binding proteins and TGF-beta/activin signaling components were expressed by all four cell types, but AC and LbetaT2 cells notably lacked the type II receptor for TGF-beta, TbetaRII. Overnight treatment of TM3 and TM4 cells with TGF-beta1 suppressed the levels of betaglycan mRNA by 73 and 46% of control and subsequent [(125)I]inhibin A binding by 64 and 41% of control (IC(50) of 54 and 92 pm), respectively. TGF-beta2 acted similarly. TGF-beta pretreatments commensurately decreased the [(125)I]inhibin A affinity labeling of betaglycan on TM3 and TM4 cells. TGF-beta isoforms as direct competitors blocked up to 60% of specific inhibin A binding sites on TM3 and TM4 cells but with 9- to 17-fold lower potency than when acting indirectly via regulation of betaglycan. Only the competitive action of TGF-beta was observed with TbetaRII-deficient AC and LbetaT2 cells. Neither inhibin A nor inhibin B regulated betaglycan mRNA or competed for binding of [(125)I]TGF-beta1 or -beta2. Thus, inhibin binding to its target cell types is controlled by TGF-beta through dual mechanisms of antagonism, the operation of which vary with cell context and display different sensitivities to TGF-beta. In contrast, TGF-beta binding is relatively insensitive to the presence of either inhibin A or inhibin B.
抑制素通过与β聚糖形成高亲和力复合物来隔离激活素和骨形态发生蛋白的II型受体,从而拮抗它们的作用。β聚糖是一种共受体,抑制素与转化生长因子-β(TGF-β)共享该受体。为了阐明抑制素与TGF-β之间相互作用的性质和程度,我们因此研究了:1)这些配体在结合时的相互竞争;2)抑制素和TGF-β异构体对内源性β聚糖表达的调节;3)在小鼠睾丸间质细胞(TM3)、支持细胞(TM4)、肾上腺皮质癌细胞(AC)和促性腺激素细胞(LβT2)系中,这种β聚糖调节对随后抑制素结合的影响,这些细胞系被选作抑制素局部和内分泌作用的细胞靶点模型。所有四种细胞类型均表达公认的抑制素、激活素和TGF-β结合蛋白以及TGF-β/激活素信号传导成分,但AC和LβT2细胞明显缺乏TGF-β的II型受体TβRII。用TGF-β1对TM3和TM4细胞进行过夜处理,可使β聚糖mRNA水平分别抑制至对照的73%和46%,随后[(125)I]抑制素A结合分别抑制至对照的64%和41%(IC50分别为54和92 pm)。TGF-β2的作用类似。TGF-β预处理相应降低了TM3和TM4细胞上β聚糖的[(125)I]抑制素A亲和标记。TGF-β异构体作为直接竞争者可阻断TM3和TM4细胞上高达60%的特异性抑制素A结合位点,但效力比通过调节β聚糖间接作用时低9至17倍。在缺乏TβRII的AC和LβT2细胞中仅观察到TGF-β的竞争作用。抑制素A和抑制素B均未调节β聚糖mRNA,也未竞争[(125)I]TGF-β1或-β2的结合。因此,抑制素与其靶细胞类型的结合受TGF-β通过双重拮抗机制控制,其作用机制因细胞环境而异,并且对TGF-β表现出不同的敏感性。相比之下,TGF-β的结合对抑制素A或抑制素B的存在相对不敏感。